Description:

GOG-0240 Solid Tumor Evaluation Form (Form D2MV2) Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=45826B4E-823F-4F57-E044-0003BA3F9857

Link:

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=45826B4E-823F-4F57-E044-0003BA3F9857

Keywords:
Versions (2) ▾
  1. 8/27/12
  2. 1/9/15
Uploaded on:

January 9, 2015

DOI:
No DOI assigned. To request one please log in.
License:
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Cervical Cancer NCT00803062 On-Study - GOG-0240 Solid Tumor Evaluation Form (Form D2MV2) - 2728202v1.0

No Instruction available.

  1. StudyEvent: GOG-0240 Solid Tumor Evaluation Form (Form D2MV2)
    1. No Instruction available.
Header Module
Target Lesion(s) Evaluation
Did the patient have measurable disease at baseline
Method of Evaluation (*)
cm
Non-target Lesion(s) Evaluation
Were there any non-target lesions reported at baseline (If no, skip to the next section)
Method of Evaluation (*)
New Target Lesion(s) At Follow-up Evaluation
Was the appearance of any new lesions documented (If no, skip to the Overall Response section below.)
Method of Evaluation (*)
Overall Response
Disease status at this assessment
Overall best confirmed response
Comments

Similar models